CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,545 | -65.2% | 1,873 | -57.1% | 0.00% | -60.0% |
| Q2 2023 | $148,240 | +189951.3% | 4,369 | +100.6% | 0.01% | +150.0% |
| Q1 2023 | $78 | +500.0% | 2,178 | +604.9% | 0.00% | +100.0% |
| Q4 2022 | $13 | -100.0% | 309 | -95.5% | 0.00% | -66.7% |
| Q3 2022 | $192,000 | -37.5% | 6,805 | -40.2% | 0.00% | -57.1% |
| Q2 2022 | $307,000 | +176.6% | 11,386 | +249.2% | 0.01% | +600.0% |
| Q1 2022 | $111,000 | -19.6% | 3,261 | -8.9% | 0.00% | -50.0% |
| Q4 2021 | $138,000 | -78.9% | 3,580 | -70.4% | 0.00% | -88.2% |
| Q3 2021 | $654,000 | +1353.3% | 12,105 | +798.7% | 0.02% | +1600.0% |
| Q2 2021 | $45,000 | -63.7% | 1,347 | -80.9% | 0.00% | -75.0% |
| Q4 2020 | $124,000 | +1450.0% | 7,052 | +45.6% | 0.00% | – |
| Q1 2020 | $8,000 | -27.3% | 4,843 | +1.1% | 0.00% | -100.0% |
| Q4 2019 | $11,000 | +120.0% | 4,789 | +92.6% | 0.00% | – |
| Q3 2019 | $5,000 | -44.4% | 2,486 | +43.8% | 0.00% | -100.0% |
| Q1 2019 | $9,000 | – | 1,729 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |